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The laboratory diagnosis of
acute viral hepatitis
C. W. Spearman
The definitive diagnosis of viral hepatitis depends on the
demonstration of the virus or of serological markers of
recent infection. The serological tests to establish the
aetiology of viral hepatitis vary from laboratory to laboratory.
Those commonly performed are discussed here. An _
algorithm (Fig. 1) is provided as a guide to the investigation
of patients with suspected hepatitis. It is stressed that the
choice of initial tests should be based on the clinical
findings in each individual patient.
Hepatitis A
Hepatitis A virus (HAV) or viral antigen can be detected in
stool and other body fluids by various techniques including
electron microscopy and molecular hybridisation to
radiolabelled cDNA probes or single-stranded RNA (viral
RNA) probes. However, these techniques are time-
consuming and expensive. By the time the patient presents
with symptoms, the infection is established and the
diagnosis is thus based on the detection of specific
antibodies to HAV by radio-immunoassay (RIA)' or enzyme-
linked immunoassay (ELlSA)?
IgM anti-HAV antibodies are detectable in the serum at
the onset of symptoms, the titres rise rapidly and may
persist for 48 - 60 days after the onset of symptoms. False
positives are rare. The presence of HAV IgG antibody alone
indicates previous exposure and thus immunity, and
excludes current infection.
Hepatitis B
Commercially available tests for the diagnosis of hepatitis B
virus (HBV) infection include tests for the detection of
HBsAg, HBeAg, HBV DNA (by hybridisation techniques),
anti-HBs, anti-HBe, IgM anti-HBc and IgG anti-HBc. For
research purposes, tests are available to detect HBV DNA
by polymerase chain reaction (PCR), HBV DNA polymerase
activity, pre-S, and pre-S2 antigens and their antibodies.
In acute hepatitis B, HBsAg is detectable during the
prodromal phase prior to the elevation of transaminases.
Although the presence of HBsAg in the serum implies active
infection, the absolute level has no clinical significance and
does not correlate with the degree of infectivity.' However, in
an individual patient, a decreasing HBsAg titre is indicative
of a resolving infection. In a minor infection, HBsAg is
cleared rapidly and the only evidence of infection may be
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(HAV IgM +ve = recent infection)
b. Hepatitis B
(i) HBsAg if +ve
J.,
(ii) HBeAg if +ve suggests active viral replication
If HBsAg -ve and clinical evidence strongly suggests acute
hepatitis B, e.g.
1. Minor infection with rapid clearing of HBsAg




If IgM +ve = acute hepatitis B
If IgG +ve = previous infection or chronic hepatitis B
Repeat serology in 3 and 6 months
HBeAg +ve at 3 months = chronic hepatitis B




Screening test - Anti-HCV if +ve .
t
Confirmatory test HCV - RNA PCR +
for specificity If persistent anti-HCV and HCV RNA PCR
positive for> 6 months = chronic infection
t
LIVER BIOPSY
If HCV RNA PCR -ve and Anti-HCV -ve
and the patient is from a high-risk group
repeat tests in 3 months.
d. Hepatitis E
Total anti-HEV Ab +Ve = acute or previous infection
IgM anti-HEV +ve = acute infection
Fig. 1. Algorithm for the investigation of patients with suspected
acute viral hepatitis.
the subsequent development of anti-HBc and anti-HBs
antibodies. Soon after HBsAg is detectable, HBV DNA and
DNA polymerase, HBeAg and anti-HBc antibodies appear in
the circulation. ELlSAs are the most widely used tests for
detecting HBsAg and anti-HBs as they are easily performed
and have similar sensitivities to RIA:
IgM anti-HBc antibodies usually develop early in acute
infection; they remain positive in high titres for up to 6
months and in low titres for longer periods after acute
hepatitis B.5 Total and IgM anti-HBc antibodies are present
during the 'window' period after HBsAg is lost but before
anti-HBs appears. IgM anti-HBc is useful in distinguishing
recent and current HBV infection6 from remote previous
infection and in diagnosing HBV infection when HBsAg is
negative, i.e. during the window period of acute hepatitis B
and in some cases of fulminant hepatitis B. Anti-HBc
antibodies are usually measured by ELlSA. ELlSA for
detecting IgM anti-HBc is designed to detect it above a pre-
defined level and is thus indicative of recent infection as IgM
anti-HBc may persist in low titres for a prolonged period.
SAMJ
ARTICLES
Detection of HBeAg in the serum is important in the clinical
evaluation of a patient with HBV infection as it usually
correlates with viral replication, active liver damage and
infectivity.3 HBeAg is detected in the serum early in acute
hepatitis B and its disappearance is followed by the
appearance of anti-HBe in resolving infection.' The
persistence of HBeAg is usually associated with ongoing viral
replication, liver damage and the development of chronic
liver disease. It is important to note that some patients who
are HBeAg-negative and anti-HBeAb-positive may still
develop chronic active hepatitis. These patients are HBV
DNA-positive and have other positive markers of viral
replication. This serological picture is also seen in individuals
with HBV mutants that replicate in the absence of HBeAg.
Seroconversion to anti-HBe may be associated with the
development of mutant strains of HBV, characterised by high
levels of HBV DNA but no expression of HBeAg. This is due
to a single point mutation in the HBV DNA which does not
permit translation of HBeAg but allows expression of HBcAg.
The mutation (a single codon of the HBeAg, just upstream of
the HBcAg initiation site, mutated to a stop codon) may be
associated with clinically aggressive disease which responds
poorly to interferon therapy. Both HBeAg and HBeAb are
measured by commercially available RIAs or ELlSAs.
HBV DNA can be detected in serum either by means of
hybridisation techniques or PCR. PCR is extremely sensitive
(1 - 3 virus genomes in serum sample) but is mainly a
research tool. Clinically, detection of HBV DNA by
hybridisation (106 genome equivalents) is more valuable as it
correlates with a high level of viral replication and is
associated with ongoing liver damage.
In acute hepatitis B, HBV DNA is not found during the
incubation period but becomes detectable after HBsAg is
present in serum at the onset of clinical symptoms. HBV
DNA tends to be cleared rapidly in acute self-limiting HBV
infection, and usually disappears before HBeAg and the
transaminase levels return to normal.
HBV DNA polymerase activity is another marker of active
viral replication but at present is used mainly as a research
tool.
Anti-HBsAb is the last marker to appear, is detectable only
after excess HBsAg has been cleared from the serum and
usually persists long-term. There may be a window period
between the loss of HBsAg and the appearance of anti-HBs.
Ten per cent of patients with acute hepatitis B never develop
anti-HBs despite clinical recovery, and occasionally chronic
carriers have both HBsAg and anti-HBs.
Pre-S, and pre-S2 antigens appear early in acute infection
and their presence generally correlates with HBV DNA
positivity and other markers of viral replication.· Pre-S
antigens tend to disappear early and this may indicate
subsequent clinical reSOlution" Persistence of pre-S
antigens has been associated with the development of
chronic HBV infection.
Anti-pre-S antibodies also develop early in infection when
HBsAg is detectable but before anti-HBs antibody appears.
Persistence of pre-S2 antigen and failure to develop pre-S2
antibodies has been associated with a poor prognosis in
fulminant hepatitis. At present, measurement of pre-S
antigens and antibodies is limited to research purposes.
Patients in whom HBsAg persists for longer than 6
months and HBeAg persists for longer than 3 months are
considered chronic carriers. Healthy carriers usually do not
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have evidence of active viral replication. In symptomatic
carriers with chronic liver disease HBsAg, HBeAg and HBV
DNA are usually present in the serum or liver.
Hepatitis C
As 75% of patients with acute hepatitis C have a mild
anicteric illness, the diagnosis is frequently not made.
Moreover, the timing of seroconversion to anti-HCV is
variable and may not be detected in patients with self-
limiting disease. Patients with post-transfusion non-A, non-B
(NANB) hepatitis usually remain anti-HCV-negative during
the early phase of the illness, but anti-HCV tests may be
transiently positive immediately after the transfusion due to
passive transfer of antibodies from the donor.,Q Occasionally,
anti-HCV antibodies appear 2 - 4 weeks after the onset of
hepatitis but usually the anti-HCV antibody only appears
months after the serum aminotransferase levels become
elevated. Thus, in the acute setting, the diagnosis of HCV
infection is still largely by exclusion of other causes.
Serological diagnosis of HCV infection depends on the
detection of HCV antibodies or HCV RNA. The anti-HCV
antibody tests include the first-generation ELlSAs which
utilise the recombinant C100-3 antigen to capture antibody.
The C100-3 ELlSA has low sensitivity and specificity although
serum anti-C100-3 was a reasonable marker for chronic
infection (in transfusion-related and sporadic NANB hepatitis)
with persistently elevated ALT levels; in acute resolving
hepatitis anti-C100-3 was only positive in 30% of cases with
seroconversion occurring after 3 - 6 months. There is also a
high false-positive rate among low-risk populations, e.g.
blood donors; with frozen sera" and in the presence of
hypergammaglobulinaemia. Assays for IgM antibodies to
C100-3 are available and although IgM anti-C100-3
antibodies may be detected as early as 4 weeks after
incubation, they are also detectable in chronic hepatitis C and
thus cannot distinguish between acute and chronic hepatitis.
Second-generation ELlSAs (Ortho) have increased
sensitivity as they incorporate extra-HCV-derived
recombinant proteins including c22c, c33c and c200 (a
composite antigen).12 Anti-c33c and anti-c22c antibodies
occur more frequently in serum and earlier in the course of
disease than anti-c100-3 antibodies.
Third-generation ELlSAs, which test for antibodies to core,
NS3 and NS5 antigens (combination of peptides from both
structural and non-structural regions), further increase
sensitivity of HCV detection in acute and chronic NANB
hepatitis.
Supplementary tests involving recombinant immunoblot
assays (RIBAs) have increased specificity. The second-
generation RIBA4 (Ortho) tests for antibodies to C100-3,
5-1-1 (proteins from NS3/NS4 regions), c33c and c22-3.
RlBA4 is useful in excluding false-positive ELlSA results and
there is good correlation between RIBA4 positivity and
viraemia as determined by PCR detection of HCV RNA.",14
Direct tests for HCV antigens in serum are not yet
available. HCV RNA is at present the best marker of
viraemia and infectivity. HCV RNA is measured by means of
PCR, Detection of HCV RNA by PCR may confirm viraemia
in patients who remain HCV antibody-negative and is also
detectable in blood much earlier than other markers; tests
may be positive within days of the infection, The sensitivity
of the PCR depends on the primers used and primers
derived from the 5' -UTR region are generally more sensitive
as this region is highly conserved among HCV isolates.
Quantitative HCV RNA tests have recently been developed
which will enable HCV RNA titres to be correlated with
serum aminotransferase values, response to antiviral agents
and severity of liver disease.
Hepatitis D
Acute hepatitis D occurs either as superinfection in a
chronic hepatitis B carrier or simultaneously with acut~
hepatitis B as a co-infection.
Total anti-HDV and IgM anti-HDV antibodies can be
measured by ELlSAs. Total anti-HDV antibodies are usually
negative in the acute phase of the illness with
seroconversion occurring late in the clinical course of the
disease.'s In patients with acute, self-limiting co-infection
with both HDV and HBV, total anti-HDV titres are low and
remain detectable for several months. Persistent high total
anti-HDV titres usually occur in chronic disease where a
patient with chronic HBV infection becomes superinfected
with HDV.'6
IgM anti-HDV antibodies are usually positive in acute
cases but do not distinguish between HDV/HBV co-infection
and superinfection. 17 In self-limiting co-infections, the IgM
anti-HDV response is usually short-lived, whereas in chronic
HDV infection, the IgM levels vary from being undetectable
to fluctuating to high.
Delta antigen is detectable by ELlSA during the late
incubation period of acute hepatitis D and may persist into
the symptomatic phase. In chronic HDV infection, delta
antigen is often undetectable in serum with the ELlSA
technique but is usually positive if immunoblotting is used.
HDV RNA in serum can be detected by dot hybridisation
using either cDNA or single-stranded RNA probes for HDV.
In acute infection, HDV RNA is usually positive during the
symptomatic phase, becoming negative after clinical
recovery,
Hepatitis D is thought not to be a problem in South Africa,
and tests for hepatitis b should be reserved for patients with
chronic HBV infection who develop unexpected progressive
liver disease.
Hepatitis E
Total anti-HEV antibodies (IgM and IgG) can now be
measured by an ELlSA (Abbott) which has a 98% sensitivity
in acute infection. Specificity of the test is not yet known.
This test should be limited to those cases of acute hepatitis
with a likely epidemiological history and where viral markers
for hepatitis A, Band C are negative.
Hepatitis F and G
There are no serological markers for either of these two
hepatidides. Hepatitis F is an epidemiological entity that
presents as fulminant or subfulminant hepatitis. Hepatitis G
also presents as a subfulminant or fulminant hepatitis and is
associated histologically with a giant cell hepatitis.
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It is important to establish the aetiology of acute viral
hepatitis in order to treat patients and their contacts
appropriately and to limit the spread of infection. Although
a careful clinical history and biochemical markers are
important, diagnosis depends on specific serological testing.
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Most cases of hepatitis which are due to viral infection or
drug injury will resolve promptly. Indeed, in most instances
elevated transaminases may be expected to return to
normal levels within 3 months. However, in some instances
inflammation does not settle but becomes established as a
chronic illness. Although the patient may be asymptomatic,
the transaminases are intermittently or permanently
elevated, liver biopsy shows continuing damage, and there
may be evidence of ongoing viral replication. The whole
process is associated with a high risk of progression to
cirrhosis, chronic liver failure and hepatocellular carcinoma.
These then are the parameters which define the entity of
chronic hepatitis.
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Clinically the disorder is defined by demonstrating·
evidence of inflammation that has been present for at least 6
months.' The terminology of chronic hepatitis is confusing.
For many years the terms chronic persistent hepatitis (CPH)
and chronic active hepatitis (CAH) have been employed.'.2
The two were distinguished histologically by the degree and
morphological pattern of inflammation. Thus, in CPH
inflammation was confined to the portal tracts with no
periportal inflammation or inflammation within the hepatic
lobule, whereas in CAH hepatocyte necrosis and fibrosis
were evident. The distinction was believed to have important
clinical and prognostic consequences, CPH denoting a
relatively benign disease, whereas CAH was likely to
progress to cirrhosis. The terms were originally applied to
the auto-immune variety of chronic hepatitis, but have been
extended to other forms of hepatitis, and to chronic viral
hepatitis in particular, where the distinction is less useful.3
Histological changes may not be uniformly distributed
throughout the liver - thus being open to sampling error -
and may also change with time; hence demonstration of the
features of CPH now offer no guarantee that the course will
be benign, or that a repeat biopsy will not show aggressive
changes. Indeed, it is the presence of virus and its
replicative status that will determine the progression of the
disease,' and histology is at best an indirect reflection of
this. Thus the terms CPH and chronic lobular hepatitis (a
later addition to the family) are now discouraged. It is
appropriate to consider all cases as chronic hepatitis (CH),
and to qualify the term further by cause, severity and
histological appearance. Thus one may speak of mild CAH
secondary to chronic hepatitis B viral infection with
inflammation limited to the portal tracts, or of severe auto-
immune CAH showing hepatocyte necrosis and fibrosis
linking adjacent portal tracts.
Causation
The important causes of chronic hepatitis are listed in
Table I. The major categories are type Band C viral
hepatitis, auto-immune chronic hepatitis (AICH) and drug-
induced chronic hepatitis. Although both primary scierosing
cholangitis (PSC) and primary biliary cirrhosis (PBC) may
present with some of the histological features of CH, they
are usually distinguished from AICH by their other
characteristic features. There are in addition a few other





Overlap with primary biliary cirrhosis, primary sclerosing
cholangitis
Drug-induced hepatitis
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